BlackRock Fund Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | $21.5M | Buy |
3,401,744
+374,149
| +12% | +$2.37M | ﹤0.01% | 2142 |
|
|
2016
Q3 | $13.4M | Buy |
3,027,595
+177,357
| +6% | +$782K | ﹤0.01% | 2299 |
|
|
2016
Q2 | $8.1M | Buy |
2,850,238
+49,452
| +2% | +$140K | ﹤0.01% | 2523 |
|
|
2016
Q1 | $7.93M | Buy |
2,800,786
+11,202
| +0.4% | +$31.7K | ﹤0.01% | 2488 |
|
|
2015
Q4 | $28.8M | Sell |
2,789,584
-122,144
| -4% | -$1.26M | 0.01% | 1822 |
|
|
2015
Q3 | $33.2M | Buy |
2,911,728
+88,010
| +3% | +$1M | 0.01% | 1685 |
|
|
2015
Q2 | $42.2M | Sell |
2,823,718
-37,182
| -1% | -$555K | 0.01% | 1635 |
|
|
2015
Q1 | $25.8M | Buy |
2,860,900
+56,359
| +2% | +$509K | 0.01% | 1934 |
|
|
2014
Q4 | $34.1M | Buy |
2,804,541
+256,371
| +10% | +$3.12M | 0.01% | 1732 |
|
|
2014
Q3 | $24.9M | Sell |
2,548,170
-9,942
| -0.4% | -$97.2K | 0.01% | 1815 |
|
|
2014
Q2 | $32.6M | Buy |
2,558,112
+1,659,980
| +185% | +$21.2M | 0.01% | 1694 |
|
|
2014
Q1 | $9.5M | Buy |
898,132
+63,343
| +8% | +$670K | ﹤0.01% | 2433 |
|
|
2013
Q4 | $6.34M | Buy |
834,789
+686,454
| +463% | +$5.22M | ﹤0.01% | 2662 |
|
|
2013
Q3 | $1.08M | Buy |
148,335
+24,350
| +20% | +$177K | ﹤0.01% | 3177 |
|
|
2013
Q2 | $192K | Buy |
+123,985
| New | +$192K | ﹤0.01% | 3331 |
|